The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gene Therapy in Cardiovascular Disorder Market Research Report 2025
Synopsis
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Global Gene Therapy in Cardiovascular Disorder market is projected to reach US$ 1351.3 million in 2029, increasing from US$ 178 million in 2022, with the CAGR of 21.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Gene Therapy in Cardiovascular Disorder market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Gene Therapy in Cardiovascular Disorder market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Renovacor
Gene Biotherapeutics
AskBio
Human Stem Cells Institute
Novartis
Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy
Segment by Application
Heart Disease
Vascular Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Gene Therapy in Cardiovascular Disorder report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Global Gene Therapy in Cardiovascular Disorder market is projected to reach US$ 1351.3 million in 2029, increasing from US$ 178 million in 2022, with the CAGR of 21.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Gene Therapy in Cardiovascular Disorder market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Gene Therapy in Cardiovascular Disorder market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Renovacor
Gene Biotherapeutics
AskBio
Human Stem Cells Institute
Novartis
Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy
Segment by Application
Heart Disease
Vascular Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Gene Therapy in Cardiovascular Disorder report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Therapy in Cardiovascular Disorder Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Viral Gene Therapy
1.2.3 Non-viral Gene Therapy
1.3 Market by Application
1.3.1 Global Gene Therapy in Cardiovascular Disorder Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Heart Disease
1.3.3 Vascular Disease
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Therapy in Cardiovascular Disorder Market Perspective (2018-2029)
2.2 Gene Therapy in Cardiovascular Disorder Growth Trends by Region
2.2.1 Global Gene Therapy in Cardiovascular Disorder Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Gene Therapy in Cardiovascular Disorder Historic Market Size by Region (2018-2023)
2.2.3 Gene Therapy in Cardiovascular Disorder Forecasted Market Size by Region (2024-2029)
2.3 Gene Therapy in Cardiovascular Disorder Market Dynamics
2.3.1 Gene Therapy in Cardiovascular Disorder Industry Trends
2.3.2 Gene Therapy in Cardiovascular Disorder Market Drivers
2.3.3 Gene Therapy in Cardiovascular Disorder Market Challenges
2.3.4 Gene Therapy in Cardiovascular Disorder Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Therapy in Cardiovascular Disorder Players by Revenue
3.1.1 Global Top Gene Therapy in Cardiovascular Disorder Players by Revenue (2018-2023)
3.1.2 Global Gene Therapy in Cardiovascular Disorder Revenue Market Share by Players (2018-2023)
3.2 Global Gene Therapy in Cardiovascular Disorder Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gene Therapy in Cardiovascular Disorder Revenue
3.4 Global Gene Therapy in Cardiovascular Disorder Market Concentration Ratio
3.4.1 Global Gene Therapy in Cardiovascular Disorder Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy in Cardiovascular Disorder Revenue in 2022
3.5 Gene Therapy in Cardiovascular Disorder Key Players Head office and Area Served
3.6 Key Players Gene Therapy in Cardiovascular Disorder Product Solution and Service
3.7 Date of Enter into Gene Therapy in Cardiovascular Disorder Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Therapy in Cardiovascular Disorder Breakdown Data by Type
4.1 Global Gene Therapy in Cardiovascular Disorder Historic Market Size by Type (2018-2023)
4.2 Global Gene Therapy in Cardiovascular Disorder Forecasted Market Size by Type (2024-2029)
5 Gene Therapy in Cardiovascular Disorder Breakdown Data by Application
5.1 Global Gene Therapy in Cardiovascular Disorder Historic Market Size by Application (2018-2023)
5.2 Global Gene Therapy in Cardiovascular Disorder Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Gene Therapy in Cardiovascular Disorder Market Size (2018-2029)
6.2 North America Gene Therapy in Cardiovascular Disorder Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Gene Therapy in Cardiovascular Disorder Market Size by Country (2018-2023)
6.4 North America Gene Therapy in Cardiovascular Disorder Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gene Therapy in Cardiovascular Disorder Market Size (2018-2029)
7.2 Europe Gene Therapy in Cardiovascular Disorder Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Gene Therapy in Cardiovascular Disorder Market Size by Country (2018-2023)
7.4 Europe Gene Therapy in Cardiovascular Disorder Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy in Cardiovascular Disorder Market Size (2018-2029)
8.2 Asia-Pacific Gene Therapy in Cardiovascular Disorder Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Gene Therapy in Cardiovascular Disorder Market Size by Region (2018-2023)
8.4 Asia-Pacific Gene Therapy in Cardiovascular Disorder Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gene Therapy in Cardiovascular Disorder Market Size (2018-2029)
9.2 Latin America Gene Therapy in Cardiovascular Disorder Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Gene Therapy in Cardiovascular Disorder Market Size by Country (2018-2023)
9.4 Latin America Gene Therapy in Cardiovascular Disorder Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy in Cardiovascular Disorder Market Size (2018-2029)
10.2 Middle East & Africa Gene Therapy in Cardiovascular Disorder Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Gene Therapy in Cardiovascular Disorder Market Size by Country (2018-2023)
10.4 Middle East & Africa Gene Therapy in Cardiovascular Disorder Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Renovacor
11.1.1 Renovacor Company Detail
11.1.2 Renovacor Business Overview
11.1.3 Renovacor Gene Therapy in Cardiovascular Disorder Introduction
11.1.4 Renovacor Revenue in Gene Therapy in Cardiovascular Disorder Business (2018-2023)
11.1.5 Renovacor Recent Development
11.2 Gene Biotherapeutics
11.2.1 Gene Biotherapeutics Company Detail
11.2.2 Gene Biotherapeutics Business Overview
11.2.3 Gene Biotherapeutics Gene Therapy in Cardiovascular Disorder Introduction
11.2.4 Gene Biotherapeutics Revenue in Gene Therapy in Cardiovascular Disorder Business (2018-2023)
11.2.5 Gene Biotherapeutics Recent Development
11.3 AskBio
11.3.1 AskBio Company Detail
11.3.2 AskBio Business Overview
11.3.3 AskBio Gene Therapy in Cardiovascular Disorder Introduction
11.3.4 AskBio Revenue in Gene Therapy in Cardiovascular Disorder Business (2018-2023)
11.3.5 AskBio Recent Development
11.4 Human Stem Cells Institute
11.4.1 Human Stem Cells Institute Company Detail
11.4.2 Human Stem Cells Institute Business Overview
11.4.3 Human Stem Cells Institute Gene Therapy in Cardiovascular Disorder Introduction
11.4.4 Human Stem Cells Institute Revenue in Gene Therapy in Cardiovascular Disorder Business (2018-2023)
11.4.5 Human Stem Cells Institute Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Gene Therapy in Cardiovascular Disorder Introduction
11.5.4 Novartis Revenue in Gene Therapy in Cardiovascular Disorder Business (2018-2023)
11.5.5 Novartis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
